Cat. No.: HY-N2099

Onjisaponin B

(Synonyms: Senegin III)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB.

For research use only. We do not sell to patients.

Purity: 99.31%
CAS No.: 35906-36-6
Formula: C₇₅H₁₁₂O₃₅
Molecular Weight:1573.67

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Onjisaponin B Chemical Structure

CAS No.: 35906-36-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Caspase Isoforms :

All NF-κB Isoforms :

In Vitro

Onjisaponin B (3-50 μM, 8-24 h) activates autophagy through an Atg7, AMPK-mTOR dependent manner in PC-12 cells^[1].
Onjisaponin B (6.25-50 μM, 16-24 h) enhances the clearance of mutant huntingtin and A53T α-synuclein, lowers the toxicity and acts as a neuroprotective agent in PC-12 cells, and reduces oligomerization of α-synuclein in HeLa cells^[1].
Onjisaponin B (0.01-10 μM) reducesβ-amyloid (Aβ) production with an IC₅₀ of 10 μM without affecting BACE1 or γ-secretase activity in 293T cells^[3].
Onjisaponin B (20 μg/mL, 8-50 h) inhibits the activation of Cas3 through p65, reducing radiation-induced cell apoptosis and helping to prevent radiation injury in TC, V79 and MTEC-1 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Autophagy Assay^[1]

Cell Line:

PC-12 cells transfected with GFP-LC3 plasmids
Concentration:

6.25, 12.5, 25, 50 μM
Incubation Time:

24 h
Result:

Increased the formation of GFP-LC3 puncta formation in a dose-dependent manner.

Cell Viability Assay^[1]

Cell Line:

PC-12 cells transfected transiently with EGFP-HDQ 74 or myc-tagged mutant A53T α-synuclein
Concentration:

25 μM or 50 μM
Incubation Time:

48 h or 24 h
Result:

Reduced toxicity in PC-12 cells expressing either mutant huntingtin or A53T α-synuclein.

Apoptosis Analysis^[4]

Cell Line:

TC cells(thymocytes), V79 cells, MTEC-1 cells
Concentration:

20 μg/mL
Incubation Time:

8, 50, 26 h (incubated 2 hours then irradiated with radiation (TC cells: 6 h, V79 cells: 48 h, MTEC-1 cells: 24 h))
Result:

Reduced apoptosis caused by radiotherapy.

Western Blot Analysis^[1]

Cell Line:

PC-12 cells
Concentration:

3, 6.25, 12.5, 25, 50 μM
Incubation Time:

8, 16, 24 h
Result:

Increased the rate of LC3-II formation with the presence of protease inhibitors.
No obvious cytotoxicity observed.
Activated the phosphorylation of AMPK in a time- and dose-dependent manner, and the activation was accompanied by a concomitant reduction in its downstream p70S6K phosphorylation.

Western Blot Analysis^[4]

Cell Line:

V79 cells
Concentration:

20 μg/mL
Incubation Time:

2 hours prior to irradiation
Result:

Down regulated the expression levels of the activation products p-p65 and c-Cas3 induced by irradiation.
The ability to down-regulate p-p65 and c-Cas3 proteins was reduced, or even reversed in V79 cells transfected with p65 shRNA plasmid.

In Vivo

Onjisaponin B (40 mg/kg; i.g.; once) cannot pass through the blood-brain barrier (BBB), but its metabolite tenuifolin (TF) can enter the brain through the BBB in mice^[2].
Onjisaponin B (20-40 mg/kg; i.g.; daily for 12 days) ameliorates dopaminergic (DA) neurodegeneration in a MPTP (HY-15608)-induced mouse model of Parkinson’s disease (PD) through anti-oxidant and anti-inflammatory activities mediated via the RhoA/ROCK2 signaling pathway^[2].
Onjisaponin B (10 mg/kg; p.o.; daily from 4 to 7 months of age) reduces β-amyloid production and improve cognitive impairments in transgenic mice^[3].
Onjisaponin B (2.5 mg/kg; p.o.; 4 days prior to irradiation) significantly reduces pathological changes and apoptosis and the nuclear translocation of p65 in the lung tissue of p65+/- mice following radiation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J-Rela^em1Smoc mice (p65^+/- mice)^[4]
Dosage:

2.5 mg/kg
Administration:

Oral gavage (p.o.); 4 days prior to irradiation
Result:

Inhibited p65 and cas3 activation caused by p65, and significantly reduced pathological changes and apoptosis (caused by down-regulation of p65) and the nuclear translocation of p65 in the lung tissue of p65^+/- mice following radiation, but not in the thymus.

Animal Model:

C57BL/6J mice (male, 12 weeks old)^[2]
Dosage:

20, 40 mg/kg
Administration:

Intragastric gavage (i.g.); daily for 12 days
Result:

Had a neuroprotective effect on MPTP (HY-15608) induced Parkinson’s disease (PD) model mice.
Recovered MPTP-induced motor impairment.
Reduced the number of ionized calcium-binding adapter molecule 1 (IBA-1)-positive cells, suppressed microglial activation induced by MPTP.
Inhibited the secretion of IL-1β, TNF-α, and IL-6.
Decreased MDA levels but increased SOD levels, exerted antioxidant abilities in PD model mice.

Animal Model:

APPswe/PS1ΔE9 (APP/PS1) double-transgenic mice^[3]
Dosage:

10 mg/kg (200 μL (1 mg/mL) per 20 g body weight)
Administration:

Oral gavage (p.o.); daily from 4 to 7 months of age
Result:

No obvious toxic effects in mice.
Did not alter mouse locomotor activity.
Ameliorated cognitive impairments in amyloid precursor protein (APP)/ presenilin 1 (PS1) mice.
Showed significantly lower numbers of 6E10-positive Aβ plaque and reduced plaque area.

Chemical Information

CAS No. 35906-36-6
Appearance Solid
Molecular Weight 1573.67
Formula C₇₅H₁₁₂O₃₅
Color White to off-white
SMILES

OC[C@](C1=CC[C@]2([H])[C@]3(C[C@H](O)[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO)C)(CC[C@]6(C(O[C@H](O[C@H](C)[C@H](OC(/C=C/C7=CC=C(OC)C=C7)=O)[C@@H]8O[C@@](O[C@@H](C)[C@H](O)[C@H]9O)([H])[C@@H]9O)[C@@H]8O[C@@](O[C@@H](C)[C@H](O[C@@](OC[C@@H](O[C@]([C@@H]([C@@H](O)[C@H]%10O)O)([H])O[C@@H]%10CO)[C@@H]%11O)([H])[C@@H]%11O)[C@H]%12O)([H])[C@@H]%12O)=O)[C@@]1([H])CC(C)(C)CC6)[C@@]2(CC[C@@]3([H])[C@]4(C)C(O)=O)C
Synonyms

Senegin III
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

EMBO Mol Med

Reelin-LRP8 signaling mediates brain dissemination of breast cancer cells via abluminal migration. [Abstract]

2025 Jun 12. PMID: 40506610
Biochem Biophys Res Commun

Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]

2025 Jun 10:776:152184. PMID: 40517671

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (63.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.6355 mL

3.1773 mL

6.3546 mL

5 mM

0.1271 mL

0.6355 mL

1.2709 mL

10 mM

0.0635 mL

0.3177 mL

0.6355 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (1.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (1.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wu AG, et al. Onjisaponin B derived from Radix Polygalae enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells. Int J Mol Sci. 2013 Nov 15;14(11):22618-41. [Content Brief]

[2]. Peng F, et al. The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neuroreport. 2020 Apr 8;31(6):456-465. [Content Brief]

[3]. Li X, et al. Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce β-Amyloid Production and Improve Cognitive Impairments. PLoS One. 2016 Mar 8;11(3):e0151147. [Content Brief]

[4]. Wang TY, et al. Targeting p65 to inhibit Cas3 transcription by Onjisaponin B for radiation damage therapy in p65+/- mice. Phytomedicine. 2022 Sep;104:154317. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.6355 mL	3.1773 mL	6.3546 mL	15.8864 mL
	5 mM	0.1271 mL	0.6355 mL	1.2709 mL	3.1773 mL
	10 mM	0.0635 mL	0.3177 mL	0.6355 mL	1.5886 mL
	15 mM	0.0424 mL	0.2118 mL	0.4236 mL	1.0591 mL
	20 mM	0.0318 mL	0.1589 mL	0.3177 mL	0.7943 mL
	25 mM	0.0254 mL	0.1271 mL	0.2542 mL	0.6355 mL
	30 mM	0.0212 mL	0.1059 mL	0.2118 mL	0.5295 mL
	40 mM	0.0159 mL	0.0794 mL	0.1589 mL	0.3972 mL
	50 mM	0.0127 mL	0.0635 mL	0.1271 mL	0.3177 mL
	60 mM	0.0106 mL	0.0530 mL	0.1059 mL	0.2648 mL

Keywords

Onjisaponin B

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Onjisaponin B

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Onjisaponin B

All Caspase Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Onjisaponin B Related Classifications

HY-N2099 Related Classifications